Genetically nominated cardiovascular-kidney-metabolic features are not consistently more responsive to weight-loss and cardiometabolic interventions

Background Substantial cardiovascular and kidney risk persists after successful weight loss. Whether features that genetics implicates in cardiovascular-kidney-metabolic (CKM) disease show larger short-term responses to weight-loss and cardiometabolic interventions than other features is unknown. Methods Across four molecular layers (proteome, transcriptome, methylome, metabolome), we applied layer-specific cis-Mendelian randomization with colocalization or summary-data shared-signal filtering against eight CKM genome-wide association studies. Within 13 omics-by-intervention analyses (diet, bariatric surgery, empagliflozin, behavioral weight loss), we compared response magnitude between nominated and adequately-instrumented non-nominated features using rank-based Cliff's {delta} ; methylation was baseline-variance-matched and directional analyses exploratory. Results Here we show genetic nomination is not consistently associated with larger observed response magnitude: estimates are small (|{delta}| < 0.08 in all 13; median |{delta}| = 0.03), near zero (descriptive pooled {delta} = +0.001, 95% CI -0.013 to +0.015; I2 = 0%), none significant by label-permutation, though smaller proteomic and transcriptomic analyses remain compatible with modest differences. Nominated proteins and metabolites frequently changed (48--71% were responsive), at rates similar to comparison features; the null is not one of universal non-response. Nominated CpG sites have lower baseline inter-individual variance (Mann-Whitney P = 1.7 x 10-6 to 4 x 10-3 at the primary nomination tiers), and apparent methylation persistence attenuates after variance-matching. Conclusions Under the definitions and datasets studied, genetic target support does not consistently predict pharmacodynamic responsiveness and should not be read as a treatment-response or reversibility biomarker; baseline dynamic range should be assessed and controlled when comparing molecular change across selected features. Nominated features are not shown unchanged or to explain residual risk; same-subject longitudinal studies are needed to test prognostic or therapeutic value.